Brief: 3Sbio Says Study On Narfuraphine Hydrochloride Tablets Reached Preset Clinical Study Endpoint
21/07/2021 14:53
July 21 (Reuters) - 3SBio Inc 1530.HK :
* 3SBIO INC- STUDY ON NARFURAPHINE HYDROCHLORIDE ORALLY
DISINTEGRATING TABLETS REACHED PRESET CLINICAL STUDY ENDPOINT
* 3SBIO INC- EXPECTS NEW DRUG APPLICATION WILL BE SUBMITTED
TO
NMPA OF PRC IN Q4 OF 2021
Source text for Eikon: ID:nHKS6sBT9Z
Further company coverage: 1530.HK
(Reuters.briefs@thomsonreuters.com)